Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650295 | 0.74 | CSNK1A1 (0.54) | CSNK1A1TYRO3DYRK1BKEAP1NFE2L2 | |
| SCHEMBL3914170 | 0.74 | CSNK1A1 (0.44) | CSNK1A1TYRO3DYRK1BKEAP1NFE2L2 | |
| SCHEMBL14313208 | 0.72 | PIM1 (0.38) | — | |
| SCHEMBL3222329 | 0.71 | BCAT2 (0.38) | CSNK1A1TYRO3DYRK1BKEAP1NFE2L2 | |
| SCHEMBL3218782 | 0.71 | — | — | |
| SCHEMBL28665677 | 0.69 | BCAT2 (0.51) | CSNK1A1TYRO3DYRK1BKEAP1NFE2L2 | |
| SCHEMBL3344539 | 0.69 | PARP1 (0.39) | CSNK1A1TYRO3DYRK1BKEAP1NFE2L2 | |
| SCHEMBL6231660 | 0.69 | ALDH1A1 (0.41) | — | |
| SCHEMBL17478606 | 0.68 | MKNK1 (0.38) | CSNK1A1TYRO3DYRK1B | |
| SCHEMBL3225838 | 0.67 | KDM4E (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | CSNK1A1 1855/4885TYRO3 4243/4885DYRK1B 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.